Targeting PD-L1 in non-small cell lung cancer using CAR T cells

Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) develops in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ming, Wang, Xu, Li, Wei, Yu, Xinfang, Flores-Villanueva, Pedro, Xu-Monette, Zijun Y., Li, Ling, Zhang, Mingzhi, Young, Ken H., Ma, Xiaodong, Li, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426958/
https://www.ncbi.nlm.nih.gov/pubmed/32792499
http://dx.doi.org/10.1038/s41389-020-00257-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426958/
https://www.ncbi.nlm.nih.gov/pubmed/32792499
http://dx.doi.org/10.1038/s41389-020-00257-z

Ejemplares similares